Your session is about to expire
Triumeq vs Complera
Introduction
For patients living with HIV, the goal is to suppress their viral load and increase their CD4 cell count, which helps in strengthening the immune system. Triumeq and Complera are two such antiretroviral drugs that are commonly prescribed for this purpose. They each contain different active ingredients but both aim to prevent the virus from multiplying in patients' bodies. Triumeq combines three medications: dolutegravir, abacavir, and lamivudine. It works by blocking a specific enzyme called integrase that HIV uses to replicate itself within CD4 cells. On the other hand, Complera contains rilpivirine (a non-nucleoside reverse transcriptase inhibitor), tenofovir disoproxil fumarate (nucleotide reverse transcriptase inhibitor) and emtricitabine (a nucleoside analogue). These components work synergistically to inhibit another enzyme called reverse transcriptase, which is also critical for HIV replication.
Triumeq vs Complera Side By Side
| Attribute | Triumeq | Complera |
|---|---|---|
| Brand Name | Triumeq | Complera |
| Contraindications | Should not be taken with dofetilide or if there's a known hypersensitivity to any component of the drug. | Should not be taken with dofetilide or if there's a known hypersensitivity to any component of the drug. |
| Cost | $3,000 for a 30-day supply | $3,400 for a 30-day supply |
| Generic Name | abacavir/dolutegravir/lamivudine | emtricitabine/rilpivirine/tenofovir disoproxil fumarate |
| Most Serious Side Effect | Hypersensitivity reactions, severe skin reactions, lactic acidosis, and signs of IRIS | Liver problems, kidney issues, lactic acidosis, bone loss |
| Severe Drug Interactions | Dofetilide | Dofetilide |
| Typical Dose | One tablet per day | One tablet per day with food |
What is Triumeq?
Triumeq and Complera are both antiretroviral medications used in the treatment of Human Immunodeficiency Virus (HIV). Triumeq is a combination medication that contains abacavir, dolutegravir, and lamivudine. It was first approved by the FDA in 2014. This medication works by inhibiting essential components of HIV replication cycle, effectively reducing the amount of virus within the body to significantly low levels. Its use is recommended for initial therapy for patients with no known or suspected resistance to any components of this drug.
On the other hand, Complera combines emtricitabine, rilpivirine, and tenofovir disoproxil fumarate into one pill taken once daily. Approved by FDA in 2011, it's generally prescribed for adults who are just starting HIV-1 treatment with viral load less than 100k copies/ml due to its potential side effects related to kidney impairment and decrease bone mineral density. Complera has fewer overall systemic adverse reactions compared to drugs that have stronger effects on immune system modulation.
What conditions is Triumeq approved to treat?
Triumeq is approved for use in the treatment of Human Immunodeficiency Virus (HIV) infections:
- As a stand-alone, one-pill therapy containing three antiretroviral drugs
- For adults and children who weigh at least 40 kg
- In patients with no known resistance to any of the three active ingredients
On the other hand, Complera is also used in HIV treatment but has different indications:
- For adult and pediatric patients 12 years or older with body weight at least 35 kg
- As initial treatment in those with no prior antiretroviral therapy history
- Or to replace a stable antiretroviral regimen in those maintaining controlled HIV viral load for at least six months
How does Triumeq help with these illnesses?
Triumeq is designed to manage HIV by combining three active ingredients: dolutegravir, abacavir, and lamivudine. These work together by inhibiting the action of enzymes essential for the replication of HIV within cells. Dolutegravir blocks an enzyme called integrase which prevents the virus from inserting its genetic material into human DNA while abacavir and lamivudine inhibit reverse transcriptase, another enzyme crucial in viral reproduction. By disrupting these processes, Triumeq can reduce the amount of HIV in a patient's body and slow down or stop further damage to their immune system.
HIV replicates itself inside human T-cells using several key enzymes that allow it to integrate with host cell DNA and produce more copies of itself. Any disruption in this process can help control the spread of infection throughout the body. Therefore, medication like Triumeq plays a vital role in managing symptoms related to this condition as well as improving overall quality-of-life for those living with chronic HIV infections.
What is Complera?
Complera is a single-tablet regimen for the treatment of HIV-1 infection in adults. It combines three active ingredients: rilpivirine, emtricitabine, and tenofovir disoproxil fumarate. Rilpivirine inhibits the replication of HIV-1 by blocking its reverse transcriptase enzyme; this prevents the conversion of viral RNA into DNA which halts further production of new virus particles. Emtricitabine and tenofovir are both nucleoside reverse transcriptase inhibitors (NRTIs) that work similarly to block the same enzyme.
FDA-approved since 2011, Complera offers an all-in-one dosing option that may be more convenient for some patients compared to multi-pill regimens like Triumeq. However, it's important to note that Complera must be taken with a meal which aids absorption of rilpivirine while taking it on an empty stomach can reduce its effectiveness.
As with any medication, there are potential side effects such as insomnia, headache or rash; however one distinct disadvantage when compared to other antiretroviral therapy (ART) such as Triumeq might include potentially lower bone mineral density due to tenofovir.
What conditions is Complera approved to treat?
Complera, a combination antiretroviral medication, is approved for the treatment of:
- HIV-1 infection in adults who are either starting their first antiretroviral therapy and have no known resistance to the non-nucleoside reverse transcriptase inhibitor drug class
- Or, those patients already being treated with HIV medications who have been virologically suppressed (with an undetectable viral load) for at least six months.
How does Complera help with these illnesses?
Complera is a combination antiretroviral medication used for the treatment of HIV. It consists of three active ingredients: emtricitabine, rilpivirine, and tenofovir disoproxil fumarate, which work together to inhibit the replication process of HIV in different ways. Emtricitabine and tenofovir are nucleoside reverse transcriptase inhibitors (NRTIs), while rilpivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI). This differing mechanism allows Complera to effectively suppress viral replication in patients with varying levels of disease progression.
Just as Wellbutrin works by increasing the levels of norepinephrine available in the brain, Complera functions by inhibiting HIV's ability to replicate within human cells. Its unique blend of NRTIs and NNRTI can make it an effective option for those who have not responded well to other forms of antiretroviral therapy such as Triumeq or may be combined with other medications depending on individual patient circumstances.
How effective are both Triumeq and Complera?
Both Triumeq and Complera have established histories of success in treating patients with HIV, and they were approved by the FDA within a few years of each other. As they act on different aspects of the virus's lifecycle, they may be prescribed under different circumstances. The effectiveness of Triumeq and Complera in managing HIV was directly studied in a double-blind clinical trial; both drugs exhibited similar efficacy in suppressing viral loads as well as comparable safety profiles.
A review indicated that Triumeq is effective at suppressing viral load from the first week of treatment, its side effect profile is favorable over many other antiretroviral medications, and it is generally well-tolerated even among diverse populations. The same study reports that Triumeq has become one of the most widely-prescribed antiretroviral regimens worldwide. Furthermore, due to its combination nature (it contains three active ingredients), there’s an extensive history studying its effectiveness in treating HIV.
A meta-analysis showed that Complera seems to be more effective than placebo in controlling HIV infection, and appears similar in efficacy to other common antiretroviral therapies. Nonetheless, data confirming its efficacy as a stand-alone regimen are less robust than for Triumeq. Further investigations into whether or not Complera significantly augments the effect of other HIV treatments are ongoing. Due to its unique pharmacology (containing tenofovir alafenamide instead of tenofovir disoproxil fumarate), Complera might be an optimal choice for patients who need reduced bone or kidney side effects associated with older forms of tenofovir.
Find Top Clinical Trials
Choose from over 30,000 active clinical trials.
At what dose is Triumeq typically prescribed?
Oral dosages of Triumeq and Complera are both one tablet per day for the treatment of HIV-1 infection in adults and children who weigh at least 40 kg. Studies have indicated that this dosage is sufficient for controlling the viral load in most people. For patients new to antiretroviral therapy, or those switching from a stable regimen, they can be started on either medication immediately. In both cases, regular monitoring is necessary to evaluate the response and adjust treatment if necessary. The maximum dosage that should not be exceeded in any case is one tablet per day.
At what dose is Complera typically prescribed?
Complera treatment for HIV begins with a dosage of one tablet per day. This tablet combines 200 mg emtricitabine, 25 mg rilpivirine, and 300 mg tenofovir; thus providing a comprehensive antiretroviral regimen in a single dose. It's important to note that this medication should be taken with food since taking it on an empty stomach can lead to sub-optimal drug levels in the blood which may decrease its effectiveness. The maximum daily dose is one tablet per day and no increase is advised due to potential toxicity concerns. If there's no significant response or if side effects become intolerable after several weeks of therapy, alternative treatments may need to be considered under your doctor’s guidance.
What are the most common side effects for Triumeq?
Common side effects of Triumeq can include:
- Insomnia (difficulty sleeping)
- Headache
- Fatigue (tiredness)
- Dizziness
- Nausea, vomiting and diarrhea
- Skin rash or itching
- Abdominal discomfort or bloating
- Changes in body fat distribution
- Anorexia (loss of appetite)
Comparatively, common side effects associated with Complera may include:
- Dyspepsia (burning, discomfort, or pain in the digestive tract)
- Rash
- Diarrhea and nausea
- Headaches and dizziness
- Depression/anxiety -Nightmares/abnormal dreams.
Both medications should be monitored closely for potential liver problems, as well as other serious complications. Always contact your healthcare provider if you experience these symptoms or if they worsen over time.
Are there any potential serious side effects for Triumeq?
While Triumeq is generally well-tolerated, it does have potential side effects that may require immediate medical attention. These include:
- A hypersensitivity reaction characterized by rash, fever, and organ dysfunction
- Severe skin reactions such as Stevens-Johnson syndrome or toxic epidermal necrolysis which are marked by red or purple skin rash with blistering and peeling
- Changes in vision including blurry vision or eye pain
- Rapid heartbeat, shortness of breath, or feelings of passing out; Low magnesium levels causing symptoms like irregular heartbeat, persistent muscle spasms, seizures
- Lactic acidosis – a buildup of lactic acid in your blood; symptoms can include nausea/vomiting, sudden unusual stomach discomfort followed by feeling weak/light-headed/faint (especially when standing), rapid breathing
- Signs of an immune system change known as IRIS (Immune Reconstitution Inflammatory Syndrome): new signs/symptoms from previous infections
If you experience any of the above while taking Triumeq seek medical help immediately.
What are the most common side effects for Complera?
Complera, another potent HIV medication, may have various side effects that an individual should be aware of:
- Nausea or vomiting
- Diarrhea or stomach discomfort
- Headache and dizziness
- Insomnia and abnormal dreams
- Rash, itching or discoloration of the skin
- Changes in body fat distribution (loss or gain)
- Depressive disorders (depression, suicidal ideation)
- Musculoskeletal pain such as muscle stiffness, spasm and joint pain
Remember it's always crucial to discuss these potential side effects with your healthcare provider before starting on Complera.
Are there any potential serious side effects for Complera?
While Complera is generally considered safe and effective, it's important to be aware of some potential severe side effects. These may include:
- Allergic reactions such as skin rash or hives, itching, difficulty breathing or swallowing, swelling in your face or throat
- Changes in mood behavior such as depression or anxiety; suicidal thoughts
- Liver problems including upper stomach pain, loss of appetite, dark urine coloration
- Kidney issues like urinating less than usual to not at all
- Lactic acidosis which could present with symptoms like unusual muscle pain and weakness; trouble breathing; uneven heart rate; vomiting; feeling cold especially in arms and legs
- Bone loss (osteopenia/osteoporosis) that can result in bone pain
If you experience any of these side effects while on Complera regimen, it's crucial to seek immediate medical attention.
Contraindications for Triumeq and Complera?
Both Triumeq and Complera, like most antiretroviral medications for HIV treatment, can sometimes cause or worsen symptoms of depression in some people. If you notice your mood worsening, or an increase in suicidal thoughts or behavior, it is crucial that you seek immediate medical attention.
Neither Triumeq nor Complera should be taken if you are currently taking, or have recently stopped taking certain other medications such as dofetilide (a medication used to treat irregular heartbeat) due to the risk of life-threatening interactions. Always disclose all current and recent medications to your physician; drugs such as dofetilide will require a period of about two weeks to clear from your system before starting treatment with either Triumeq or Complera.
How much do Triumeq and Complera cost?
For the brand name versions of these drugs:
- The price for a 30-day supply of Triumeq (600 mg/50 mg/300 mg) averages around $3,000, which works out to approximately $100/day.
- The cost for 30 tablets of Complera (200 mg/25 mg/300 mg) is close to $3,400, working out to about $113/day.
Thus, if you are taking one tablet per day as recommended for most patients with HIV infection, then brand-name Triumeq is less expensive than Complera on a per-day treatment basis. Please note that cost should not be your primary consideration in determining which of these drugs is right for you.
Currently, there are no generic versions available in the United States for either Triumeq or Complera due to patent laws and regulations; therefore costs remain high. These medications may be covered by insurance plans under certain conditions so it's advisable to check with your healthcare provider or insurer.
Popularity of Triumeq and Complera
Triumeq, a combination antiretroviral medication containing dolutegravir, abacavir and lamivudine, was estimated to have been prescribed to approximately 210,000 people in the United States in 2020. This accounted for nearly 13% of all HIV prescriptions. Triumeq is often chosen as an initial treatment for individuals newly diagnosed with HIV due to its high barrier to resistance and low pill burden.
On the other hand, Complera which combines rilpivirine, emtricitabine and tenofovir disoproxil fumarate was prescribed to about 185,000 people in the USA during that same year. Within the US market for HIV medications in use today, it represents just under 12%. The prevalence of Complera has remained relatively steady over recent years despite newer treatments emerging onto the market. It's worth noting that choosing between these two drugs can depend on numerous factors related individual patient health profiles including kidney function and genetic predisposition towards hypersensitivity reactions.
Conclusion
Both Triumeq and Complera are established antiretroviral medications used to manage HIV/AIDS. They have been extensively studied in clinical trials, with data showing that they offer better control of the virus compared to placebo treatments. Sometimes these medications may be used together under carefully monitored conditions by a physician as they can interact with each other.
The main difference between them lies in their composition: Triumeq contains abacavir/dolutegravir/lamivudine, while Complera comprises emtricitabine/rilpivirine/tenofovir disoproxil fumarate. These different combinations mean they work on different stages of the viral replication process.
Triumeq is often considered a first-line treatment option due to its high potency and barrier to resistance. On the other hand, Complera might be preferred for patients who cannot tolerate abacavir or those who need a regimen with fewer drug-drug interactions.
Generic versions are available for both drugs, which can lead to significant cost savings especially for patients paying out-of-pocket. An adjustment period might be necessary when starting either medication, meaning full effects may not be immediately apparent.
In terms of side effects, both medicines have similar profiles including potential risks like kidney problems or changes in body fat distribution. However, it's also worth noting that Triumeq has less chance of causing psychiatric symptoms compared to Complera. For both drugs, regular monitoring is required especially during initial therapy phases; if there’s any worsening of symptoms or onset of new ones such as depressive thoughts or suicidal ideation immediate medical attention should be sought.